Developing a New Approach to Treat Pain
At EicOsis, we are addressing the opioid crisis by developing a novel, safe and effective oral treatment for people and animals suffering from pain.
EicOsis’s drug candidate EC5026 has been granted Fast Track designation by the US FDA for the treatment of neuropathic pain. EC5026 is currently undergoing Phase 1 human clinical trials. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application.
Chronic pain affects 100 million Americans and causes a substantial physical and emotional impact on their lives. Current treatments for pain are insufficient, and patients are often prescribed opioids. Increased prescription of opioids has led to a widespread public health emergency, the US Opioid Crisis. There is an unmet need for safe, non-addictive and effective pain medications that can help pain patients and fight the US Opioid Crisis.
At EicOsis we are developing a new approach to treat pain by inhibiting the soluble Epoxide Hydrolase (sEH), a key regulatory enzyme. Inhibiting sEH increases the levels of naturally occurring anti-inflammatory and pain-relieving compounds. Our first drug candidate is currently undergoing Phase 1 human clinical trials. Learn more about EicOsis Human Health.
EicOsis is advancing its first drug candidate to human clinical trials with the support of funding from federal grants and angel investors.
October, 2019 – EicOsis receives SBIR grant award from NCI/NIH
October, 2019 – EicOsis receives $15 M from NIDA/NIH as part of the HEAL Initiative
March, 2019 – EicOsis raises funding for Phase 1 clinical development from Open Philanthropy
January, 2019 – EicOsis receives $4 M from NIH Blueprint for Neuroscience Research to advance oral analgesic to Phase 1 clinical trials for neuropathic pain
Learn more about our funding sources.